Michelle Betz, D.O.
Sentara Neurology Specialists
As part of the Sentara Neurology Specialists team, Dr. Betz's focus is on diagnosing and treating disorders of the brain, spinal cord and nervous system. She specializes in providing quality care for patients suffering with multiple sclerosis. Multiple sclerosis is a chronic, unpredictable disease of the central nervous system that can appear withsymptoms such as muscle weakness, vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis, and blindness.
Board Certification
- American Osteopathic Board of Neurology and Psychiatry
Lake Erie College of Osteopathic Medicine
Residency and Internship:
UMPC Hamot Medical Center
Neurology
Fellowship:
UMPC Northshore Neurology
Multiple Sclerosis
JCV Antibody Study of Multiple Sclerosis Patients with Relapsing forms of MS receiving treatment with Tysabri (STRATIFY-2)
Biogen Idec, 2013
A Twelve Month, Prospective, Randomized, Active-Controlled, Open-Label Study to Evaluate the Patient Retention of Fingolimod vs. Approved first line Disease Modifying Therapies in Adults who are in Early stages of treatment for Relapsing Remitting Multiple Sclerosis.
Novartis, 2012
A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)
Biogen Idec MA, Inc., 2014
A 12-month, randomized, rater-and dose-blinded study to compare the efficacy and safety of Fingolimod 0.25 mg and 0.5 mg administered orally once daily with Glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis (ASSESS)
Novartis, 2014
Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with Fingolimod once daily or treated with another approved disease-modifying therapy (PASSAGE)
Novartis, 2014
Plegridy™ (peginterferon β-1a) Real World Effectiveness andSafety(POP)
BiogenIdec MA, Inc., 2014
A 12-month, Prospective, Randomized, active-controlled, open-label study to Evaluate the patient retention of Fingolimodvs. approved first-line disease modifying therapies in adults who are in Early stages of treatment for Relapsing remitting Multiple Sclerosis (PREFERMS)
Gilenya, 2014
A Multinational, Multicenter, Randomized, Parallel Group, Open-LabelStudy to Assess Medication Satisfaction in Patients with Relapsing Remitting MultipleSclerosis (RRMS) Treated with Subcutaneous Injections of Copaxone® (GlatiramerAcetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily (CONFIDENCE)
Teva Pharmaceutical Industries, Ltd., 2015
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine (EVOLVE-2)
Eli Lilly, 2015
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine (REGAIN)
Eli Lilly, 2015
A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy (PRO-ACT)
Sanofi, 2016
A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (PASS)
Sanofi, 2016
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis COMB157G2301 (Asclepios)
Novartis, 2016
An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness ofofatumumab in subjects with relapsing multiple sclerosis.(ALITHIOS)
Novartis 2018
Observational evaluation of effectivenessand patient-reported outcomes (PROs) in sub optimally Controlled patients previously taking injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS)(CLICK-MS)
EMD Serono 2019
Observational evaluation of effectiveness and patient-reported outcomes (PROs) in sub optimally controlled patients previously Taking oral disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) (MASTER-2)
EMD Serono 2019
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with an Interferon Beta 1a (Avonex®), in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacyand Safety.(EVOLUTION MS 1)
EMD Serono 2019